• PCSK9 inhibitors recommended by NLA for certain patient groups

    2 days ago - By Healio

    PHILADELPHIA - A National Lipid Association expert panel prepared updated recommendations for the use of PCSK9 antibody therapy at the NLA Scientific Sessions. The guidelines are an update to the 2015 National Lipid Association Recommendations for the Patient-Centered Management of Dyslipidemia: Part 2.
    Read more ...

     

  • PSCK9 inhibitor studies show benefit for patients with high LDL

    2 days ago - By Healio

    PHILADELPHIA - Numerous studies on PCSK9 inhibitors have been completed that establish their efficacy and safety in patients with high LDL, according to a presentation at National Lipid Association Scientific Sessions.“For those of us who have been in this field, it's an example of what happens when you combine genetics with biotechnology,” Christie M. Ballantyne, MD, FNLA, professor of medicine, chief of the section of cardiovascular research and director of the Center for Cardiovascular Disease Prevention at Baylor College of Medicine in Houston, and diplomate for the American Board of...
    Read more ...

     

  • LDL lowering more robust in men vs. women in concomitant PCSK9 inhibitor, statin therapy

    2 days ago - By Healio

    PHILADELPHIA - In a small cohort of patients taking PSCK9 inhibitors, men had a lower reduction in LDL than women among those also on statin therapy, according to a poster presented at the National Lipid Association Scientific Sessions.Debra Friedrich, DNP, FNP-BC, CLS, BC-ADM, FNLA, FACC, professor at University of South Florida College of Nursing, Tampa, and colleagues analyzed 97 patients at five lipid clinics.
    Read more ...